State Street SPDR S&P Pharmaceuticals ETF
XPH
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- One Iron Street Boston MA United States of America 2210
- IPO Date
- Jun 22, 2006
- CIK
- 0001064642
- Website
- ssga.com
- Similar Companies
- Business
- SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Pharmaceuticals Select Industry Index. Managed and issued by State Street Global Advisors (SSGA), now operating as State Street Investment Management, the fund employs a representative sampling strategy to track an equal-weighted index comprising U.S.-listed common stocks of companies in the pharmaceuticals sub-industry of the S&P Total Market Index, including large-, mid-, and small-cap issuers engaged in activities such as research, development, manufacturing, and marketing of prescription or over-the-counter pharmaceutical products, biopharmaceuticals, and biotechnology therapies. The ETF holds approximately 43 to 53 securities, with top positions including Johnson & Johnson, Royalty Pharma, Jazz Pharmaceuticals, Merck & Co., and Viatris; it offers investors broad exposure to the U.S. pharmaceuticals sector without market-cap weighting bias, focusing on growth and value stocks across diversified market capitalizations. Launched on June 19, 2006, XPH is domiciled in the United States with headquarters aligned to SSGA's operations in Boston, Massachusetts. The fund targets institutional and retail investors seeking sector-specific exposure to pharmaceuticals, operating exclusively within U.S. equity markets listed on NYSE, AMEX, NASDAQ National Market, and NASDAQ Small Cap exchanges. Key metrics as of late 2025 include assets under management of approximately $186 million to $211 million, a gross expense ratio of 0.35%, a dividend yield of 1.26%, and holdings diversified to mitigate company-specific risk, with a three-year beta of 0.61 and standard deviation of 18.96%. Recent developments include quarterly distributions, such as $0.0959 declared in 2025, alongside strong performance with year-to-date gains of about 28% and a 52-week high reached in December 2025 amid biotech M&A activity and healthcare sector momentum. The ETF has benefited from broader industry trends like patent expirations, revenue challenges, and policy shifts under President Trump's administration, including executive orders to streamline domestic drug production and considerations for aligning U.S. drug prices with international levels. No major acquisitions, funding rounds, or structural changes specific to XPH were reported in the last 1-2 years, though SSGA announced enhancements and closures for other portfolio ETFs in 2025.